Blood glucose monitoring at alternative sites is consistent with fingertip results in the fasting state and 120 minutes after eating but not at 60 minutes after eating or after exercise.
Read More »Diabetes In Control
Issue 157 Item 11 Nonfasting Triglyceride Levels Predict Cardiovascular Risk
Nonfasting triglyceride (TG) levels are easier to obtain than fasting TG levels and may offer significant prognostic value. That, according to the results of the Multiple Risk Factor Intervention Trial (MRFIT) published in the May 12 issue of the Archives of Internal Medicine.
Read More »Issue 150 Item 3 Blood Glucose Increase During Antihypertensive Treatment Increa
ACE-inhibitors or calcium antagonists may be better choices.
Read More »Issue 154 Item 14 Fluid Retention Reversible In Diabetics Treated With TZD’s
Thiazolidinedione-induced fluid retention in diabetics with chronic systolic heart failure (HF) is likely to be peripheral and reversible after drug withdrawal
Read More »Skipping Meals May Help, Not Hurt, Health
New findings in mice suggest that skipping the occasional meal may be good for your health.
Read More »Issue 156 Item 10 Researchers reported at the 18th Annual Scientific Meeting of
Rofecoxib significantly increased systolic blood pressure, while celecoxib (Celebrex) and naproxen did not.
Read More »Issue 152 Item 8 Hyperglycemia Plays A Key Role in Vascular Dysfunction
Despite differences in pathophysiology and metabolism, patients with type 1 and type 2 diabetes do not differ with respect to coronary vasodilator function.
Read More »Issue 153 Item 8 Repaglinide Potency Greatly Increased When Combined With Gemfib
If the combination is used, repaglinide dosage should be greatly reduced and blood glucose concentrations carefully monitored. Gemfibrozil raised the plasma concentration of repaglinide by 5.5-15.0 times and prolonged its half-life from 1.3 to 3.7 hours.
Read More »Issue 157 Item 4 Warning Against Concomitant Use of Repaglinide and Gemfibrozil
European drug regulators warned on Wednesday that Novo Nordisk’s oral antidiabetic Prandin/NovoNorm (repaglinide) can cause severe hypoglycemia if patients take the lipid-lowering agent gemfibrozil at the same time.
Read More »Britain Opens World’s First Stem Cell Bank
The world’s first embryonic stem cell bank opened in Britain on Wednesday, breaking new ground in one of the most controversial areas of medical research.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.